Big Pharma Moves and GLP-1 Market Shifts: What's New in 2025?

In this week's episode of the Downsized News, hosts Laraine and Christopher Durham discuss major updates on GLP-1 medications and their impact on various sectors. They explore how GLP-1s are changing grocery spending and highlight the introduction of the first compounded semaglutide gummy. The episode covers legal battles, including Eli Lilly's intervention in the tripeptide case and the FDA's handling of compounded medications. They also look into the approval of a generic version of Victoza, shifts in the obesity drug market, and the growing competition among pharmaceutical giants like Eli Lilly and Novo Nordisk. Finally, they discuss the potential impact of Robert F. Kennedy Jr.'s nomination as head of health and human services on the vaccine industry.

We use Mochi Health: [ Ссылка ]. Use Laraine’s code for $40 off: QIYGO8.

DOWNSIZED WEBSITE: [ Ссылка ]

JOIN CLUB DOWNSIZED: [ Ссылка ]

DOWNSIZED GLP-1 COMPANION PRODUCT STORE: [ Ссылка ]

00:00 Introduction and Overview
00:18 Meet the Hosts
01:40 Legal Battles and Market Dynamics
04:00 Impact on Grocery Spending
06:45 Generic Liraglutide Approval
08:59 Compounded Semaglutide Gummy
11:39 Eli Lilly's Obesity Market Moves
16:02 Pharmaceutical Market Projections
19:13 Conclusion and Wrap-Up

свернуть